Literature DB >> 12454124

The simpleton's error in drug development.

Michael Castro.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12454124     DOI： 10.1200/JCO.2002.99.183

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Heterotransplant mouse model cohorts of human malignancies: A novel platform for Systematic Preclinical Efficacy Evaluation of Drugs (SPEED).

Authors:  Ashutosh K Pathak; Manisha Bhutani; Pierre Saintigny; Li Mao
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

2.  HER2 expression as a potential marker for response to therapy targeted to the EGFR.

Authors:  D R Emlet; R Schwartz; K A Brown; A A Pollice; C A Smith; S E Shackney
Journal:  Br J Cancer       Date:  2006-04-24       Impact factor: 7.640

3.  Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.

Authors:  G Apolone; R Joppi; V Bertele'; S Garattini
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

4.  Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring.

Authors:  Xi-De Wang; Karen Reeves; Feng R Luo; Li-An Xu; Francis Lee; Edwin Clark; Fei Huang
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.